For Esperion Therapeutics, 2019 Could Be a Big Year [The Motley Fool]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: The Motley Fool
For Esperion Therapeutics, 2019 Could Be a Big Year On the heels of positive trials Esperion Therapeutics ( NASDAQ:ESPR More treatment options needed Each year, over 700,000 Americans suffer heart attacks and over 00,000 die because of heart disease, according to the Centers for Disease Control and ention. That's particularly discouraging given that cholesterol-lowering statins are already being used by tens of millions of people. Image source: Getty Images. Although statins can reduce the risk of major cardiovascular events by %, many patients don't adequately respond to statins, and some discontinue them because of side effects, including muscle weakness. To improve outcomes and provide another treatment option, Esperion Therapeutics has developed bempedoic acid, a drug that can lower bad cholesterol in an entirely new way. Bempedoic acid is a once-daily oral drug that works upstream of statins to reduce cholesterol production and increase the activity of cholesterol removal in the
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 [Yahoo! Finance]Yahoo! Finance
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- ESPR's page on the SEC website